- Home
- LPA vs PACB Comparison
LPA vs PACB Comparison
Compare LPA & PACB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LPA
- PACB
- Stock Information
- Founded
- LPA 2013
- PACB 2000
- Country
- LPA United States
- PACB United States
- Employees
- LPA N/A
- PACB N/A
- Industry
- LPA
- PACB Biotechnology: Laboratory Analytical Instruments
- Sector
- LPA
- PACB Industrials
- Exchange
- LPA Nasdaq
- PACB Nasdaq
- Market Cap
- LPA 310.7M
- PACB 364.2M
- IPO Year
- LPA N/A
- PACB 2010
- Fundamental
- Price
- LPA $9.01
- PACB $1.18
- Analyst Decision
- LPA
- PACB Buy
- Analyst Count
- LPA 0
- PACB 13
- Target Price
- LPA N/A
- PACB $2.46
- AVG Volume (30 Days)
- LPA 10.5K
- PACB 8.7M
- Earning Date
- LPA 05-14-2025
- PACB 05-08-2025
- Dividend Yield
- LPA N/A
- PACB N/A
- EPS Growth
- LPA N/A
- PACB N/A
- EPS
- LPA N/A
- PACB N/A
- Revenue
- LPA $44,311,428.00
- PACB $154,014,000.00
- Revenue This Year
- LPA N/A
- PACB $7.12
- Revenue Next Year
- LPA N/A
- PACB $26.83
- P/E Ratio
- LPA N/A
- PACB N/A
- Revenue Growth
- LPA 22.46
- PACB N/A
- 52 Week Low
- LPA $6.00
- PACB $1.08
- 52 Week High
- LPA $525.00
- PACB $3.85
- Technical
- Relative Strength Index (RSI)
- LPA N/A
- PACB 38.57
- Support Level
- LPA N/A
- PACB $1.22
- Resistance Level
- LPA N/A
- PACB $1.36
- Average True Range (ATR)
- LPA 0.00
- PACB 0.09
- MACD
- LPA 0.00
- PACB 0.00
- Stochastic Oscillator
- LPA 0.00
- PACB 34.48
About LPA Logistic Properties of the Americas
Logistic Properties of the Americas is a fully-integrated, internally managed real estate company that develops, owns and manages a diversified portfolio of warehouse logistics assets in Central America and the South America. It focuses on modern Class A logistics real estate in high growth and high barrier-to-entry markets that are undersupplied and have low penetration rates.
About PACB Pacific Biosciences of California Inc.
Pacific Biosciences of California Inc is a biotechnology company focused on designing, developing, and manufacturing sequencing solutions that enable scientists and clinical researchers to improve their understanding of the genome and ultimately, resolve genetically complex problems. It operates in, one reportable segment: the development, manufacturing, and marketing of an integrated platform for genetic analysis. The majority of the company's revenue is derived from Americas, followed by Asia-Pacific and Europe Middle East, and Africa.